Europe Europe accounts for more than half of Sandoz’s global sales, and the company keeps reinvesting here, from biosimilar development and manufacturing in Slovenvia and France to antibiotic production in Austria. Christophe Delenta, President Europe, explains how closely Sandoz’s success is tied to Europe, how the company plans to grow its…
USA Generics and biosimilars serve as the financial bedrock preventing the US healthcare system from collapsing under the weight of escalating drug prices. “Generic drugs account for nearly 90 percent of all prescriptions filled in the United States, yet they consume only about 12 percent of total US prescription drug spending,”…
USA Keren Haruvi, President of Sandoz North America, reflects on the company’s transformation following its spin-off from Novartis and outlines how Sandoz is positioning itself at the forefront of the evolving US generics and biosimilars landscape. She discusses the structural barriers shaping market access, from PBM dynamics to patent complexity, while…
Taiwan Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With nearly 12 years at Sandoz, including three years in his current regional role, Hsu oversees strategic initiatives to increase biosimilar…
France The top 10 companies in the French retail generics market for 2024 according to Smart Pharma Consulting’s insights on the French pharma market. Last year, Viatris and Biogaran generated more than EUR 2.9 billion in sales and, taken together, represented over half of the total French retail generic market in…
Switzerland Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and opportunities of operating a business in the company’s home market Switzerland, and the Sandoz ambition to lead the generics and…
Global As healthcare systems grapple with rising costs and the need for broader access to treatment, off-patent medicines have taken on increasing importance. With budgets under pressure and blockbuster drugs losing exclusivity, the generics market is on track to reach USD 600 billion by 2033, with these five players leading the…
China A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’ stock plunge, and BeiGene’s USD 1.33 billion CDK2 inhibitor deal with Ensem Therapeutics. Bristol Myers to pay $800 million…
Switzerland As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment Humira, the newly spun-off company has been gearing up for its independence by preparing additional biosimilar launches, signing big partnership…
Global After a turbulent five-year tenure, Kare Schultz will be stepping down as the Israeli generics giant ‘s CEO and former Sandoz chief Richard Francis will take over in January. Francis, who brings his vast industry experience at companies like Sandoz and Biogen to the role, will inherit a number of…
UK Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical innovations and the premium costs associated with them. Health inequity and access disparities exist between both rich and developing countries,…
China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals. Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…
See our Cookie Privacy Policy Here